Pregnancy Loss Rates After Midtrimester Amniocentesis

Eddleman, Keith; Malone, Fergal D.; Sullivan, Lisa M.; Dukes, Kim; Berkowitz, Richard L.; Kharbutli, Yara; Porter, T. Flint; Luthy, David A.; Comstock, Christine H.; Saade, George R.; Klugman, Susan; Dugoff, Lorraine; Craigo, Sabrina; Timor‐Tritsch, I. E.; Carr, Stephen R.; Wolfe, Honor M.; D’Alton, Mary E.

doi:10.1097/01.aog.0000240135.13594.07

Cited by 282 publications

(83 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[…] A recent meta-analysis estimated procedure-related risks of CVS and AC to be as low as 0.2% and 0.1%, respectively [27]. ” Wulff et al [26] also found that “neither CVS nor AC was associated with increased risk of miscarriage or stillbirth.” In Table 2 we provide data that shows the same results; other studies have also confirmed these findings [28,29,30]. This reduction in pregnancy loss after invasive procedures is mainly due to the application of needles better suited for aspiration and the routine control of the procedure by sonography [28].…”

Section: Why Avoid Invasive Prenatal Testing?supporting

confidence: 72%

Noninvasive Prenatal Testing - When Is It Advantageous to Apply

et al. 2017

View full text Add to dashboard Cite

Nowadays it is common sense in obstetrics that an increased risk for pregnancy loss due to invasive testing does not exist. Nonetheless, noninvasive prenatal testing (NIPT) is a hot topic, even though this approach does not provide a reduction of unintentionally induced abortions. NIPT has a number of shortcuts which are highlighted in this review, including: (1) in NIPT placental rather than fetal DNA is studied, (2) NIPT fails in 2-6% of cases, and (3) trisomy 21 accounts for only ∼50% of existing chromosomal aberrations. Thus, we agree with the literature that NIPT is a fascinating possibility to gain information on unborn life from minimal amounts of DNA. However, it remains a pure risk estimation test directed towards the detection of specific chromosomal abnormalities from peripheral blood of the pregnant woman. It is important to highlight that families buying this test, and getting a normal result, may be provided with a false sense of security. Thus, careful and comprehensive genetic counselling should be performed before the test is offered, and should include a clear explanation of the advantages and disadvantages, as well as limitations, compared to other methods.

show abstract

Section: Why Avoid Invasive Prenatal Testing?supporting

confidence: 72%

Noninvasive Prenatal Testing - When Is It Advantageous to Apply

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Consequently, amniocentesis may help to select those women who may benefit from cerclage. Although amniocentesis is an invasive procedure and the risk of pregnancy loss has been estimated at around 1% for genetic amniocentesis [24], morbidity is lower with advancement of gestation, dropping to 0.06% [25]. In fact, in our study, the frequency of rupture of membranes within 24 h after the procedure and as a late complication was low, despite the use of amniocentesis.…”

Section: Discussionmentioning

confidence: 53%

Emergency Cerclage: Improvement of Outcomes by Standardization of Management

et al. 2015

View full text Add to dashboard Cite

Introduction: Cervical dilatation followed by prolapse and ballooning of membranes into the vagina at mid-gestation is a critical situation. The aim of this study was to describe the outcome of emergency cerclage in a tertiary referral center during a 10-year period (2001-2010) in which a defined selection of women and standard protocol were introduced. Subjects and Methods: Thirty-nine cases of emergency cervical cerclage performed before 24 completed weeks were retrospectively reviewed. Data related to maternal history, diagnosis, procedure details, postoperative management and perinatal outcome were recorded. Maternal characteristics and perinatal outcomes are described. Results: Gestational age at cerclage (mean ± SD) was 22.1 ± 2.0 weeks with 61% (24/39) of women presenting bulging membranes. Gestational age at delivery and cerclage-to-delivery time (mean ± SD) were 28.6 ± 6.2 weeks and 49.1 ± 36.5 days, respectively. Only 38.5% (15/39) of the whole group and 44.1% (15/34) of those who reached 24.0 weeks delivered beyond 28 weeks of gestational age. Neonatal survival before discharge was 82.4% (28/34). Discussion: Perinatal outcomes after emergency cerclage are still poor with more than half of the cases delivering before 28 weeks. A standard protocol may help in the management of these rare cases.

show abstract

“…While AS cells can be difficult to isolate from their niches and ES cells derivation requires the disruption of embryos, AFS cells can be easily obtained without ethical concerns from the AF during termination procedures or diagnostic amniocenteses. Actually, the safety of amniocentesis has been established by several studies documenting an extremely low overall fetal loss rate (0.06-0.83%) related to this procedure 97,98 and AFS cells can be obtained from AF samples without interfering with diagnostic procedures. [99][100][101] (2) Safety.…”

Section: Cd117+ Amniotic Fluid Stem Cellsmentioning

confidence: 99%

CD117⁺amniotic fluid stem cells

Cananzi

Coppi

2012

Organogenesis

View full text Add to dashboard Cite

Pregnancy Loss Rates After Midtrimester Amniocentesis

Abstract: II-2.

Cited by 282 publications

References 8 publications

Noninvasive Prenatal Testing - When Is It Advantageous to Apply

Noninvasive Prenatal Testing - When Is It Advantageous to Apply

Emergency Cerclage: Improvement of Outcomes by Standardization of Management

CD117⁺amniotic fluid stem cells

Contact Info

Product

Resources

About

Pregnancy Loss Rates After Midtrimester Amniocentesis

Abstract: II-2.

Cited by 282 publications

References 8 publications

Noninvasive Prenatal Testing - When Is It Advantageous to Apply

Noninvasive Prenatal Testing - When Is It Advantageous to Apply

Emergency Cerclage: Improvement of Outcomes by Standardization of Management

CD117+amniotic fluid stem cells

Contact Info

Product

Resources

About

CD117⁺amniotic fluid stem cells